Reducing immune reactions to gene delivery using engineered materials
Mitigating the Immunogenicity of Engineered Aav Gene Delivery Vectors by Biomaterial-Driven Immunosuppression
['FUNDING_R21'] · CORNELL UNIVERSITY · NIH-10741139
This study is looking at ways to make gene therapy using adeno-associated viruses (AAV) work better by reducing the body's immune response, so patients with chronic and genetic diseases can receive more effective and long-lasting treatments over time.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CORNELL UNIVERSITY (nih funded) |
| Locations | 1 site (ITHACA, UNITED STATES) |
| Trial ID | NIH-10741139 on ClinicalTrials.gov |
What this research studies
This research focuses on improving the effectiveness of gene delivery using adeno-associated viruses (AAV) by reducing the immune response that can limit their use. The approach involves creating a special material that can suppress the immune system's reaction to these viral vectors, allowing for repeated treatments over time. By engineering a specific peptide that mimics natural substances in the body, the researchers aim to enhance the durability and effectiveness of AAV gene therapies for chronic and genetic diseases. This could potentially lead to better long-term outcomes for patients requiring ongoing treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with chronic or genetic diseases that may benefit from repeated gene therapy treatments.
Not a fit: Patients who do not have chronic or genetic diseases or those who are not candidates for gene therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enable more effective and longer-lasting gene therapies for patients with chronic and genetic diseases.
How similar studies have performed: Previous research has shown promise in using biomaterials to modulate immune responses, suggesting that this approach could be effective.
Where this research is happening
ITHACA, UNITED STATES
- CORNELL UNIVERSITY — ITHACA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JIANG, SHAOYI — CORNELL UNIVERSITY
- Study coordinator: JIANG, SHAOYI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.